Valuation dashboard for Kymera Therapeutics, Inc. (KYMR) with P/E N/A, P/B 7.91, EV/EBITDA -30.8 and dividend yield 0.00%. DCF, Graham Number, EPS growth, peer multiples and dividend discount models plus sector comparison against other Healthcare companies.
Kymera Therapeutics, Inc. is a biopharmaceutical company dedicated to discovering and developing pioneering small molecule therapeutics. These treatments operate by harnessing the body's inherent protein degradation system to selectively eliminate disease-causing proteins.
Analysis Summary
Kymera Therapeutics, Inc. reported revenue of $39.2M in the most recent fiscal year, growing at a 5-year CAGR of 2.9%.
Trailing-twelve-month margins: gross margin 174.5%, operating margin -396.1%, net margin -341.9%.
At $127.51 (closing price, November 2, 2026), KYMR has negative trailing earnings (P/E not meaningful) and an ROE of -22.39%. Market capitalisation stands at $10.9B, placing it among large-cap names.
Balance sheet quality for KYMR: debt-to-equity ratio of 0.05, current ratio of 11.13 over the last 12 months. A debt-to-equity below 1.0 typically signals conservative capital structure, while a current ratio above 1.5 indicates comfortable short-term liquidity.
Valuation Ratios
| Price / Book | 7.91 |
| EV / EBITDA | -30.8 |
| Dividend Yield | 0.00% |
Peer Comparison
| Symbol | Company | Market Cap | P/E | P/B | ROE |
|---|---|---|---|---|---|
| KYMR | Kymera Therapeutics, Inc. | $10.9B | 7.91 | -22.4% | |
| NRIX | Nurix Therapeutics, Inc. | $2.8B | 11.13 | 2.96 | 49.3% |
| VRTX | Vertex Pharmaceuticals Incorporated | $140.2B | 35.60 | 4.28 | 17.5% |
| 0QZU.L | Vertex Pharmaceuticals Incorporated | $134.0B | 30.25 | 6.57 | 23.3% |
| REGN | Regeneron Pharmaceuticals, Inc. | $99.0B | 21.24 | 2.92 | 15.1% |
| MRNA | Moderna, Inc. | $88.2B | 12.93 | -39.2% | |
| 0R2M.L | Regeneron Pharmaceuticals, Inc. | $86.5B | 19.22 | 2.62 | 13.8% |
| ARGX | argenx SE | $55.0B | 41.59 | 6.59 | 16.9% |
Price
| Price | $127.51 (closing price, November 2, 2026) |
| Market Cap | $10.9B |
| Exchange | NASDAQ |
| Country | US |
Profitability
| Return on Equity | -22.39% |
| Return on Invested Capital | -23.94% |
| Return on Assets | -19.77% |
| Gross Margin | 174.52% |
| Operating Margin | -396.08% |
| Net Margin | -341.87% |
Related companies: NRIX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of KYMR: Overview · Financials · Statistics · Estimates · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks